How research protocols actually dose.
Published peptide protocols are not arbitrary — the ladders, the cycles, the fasted-state timing all follow from a handful of pharmacological facts. This page explains the structure so you can read the literature fluently. It describes what researchers did. It does not tell anyone what to do.
The short version: published protocols are shaped by three facts — half-life determines dosing frequency, receptors adapt to constant stimulation, and some effects need managing over time. Those facts produce the patterns you see everywhere in the literature: titration ladders in the GLP class, cycling and pulsed timing on the GH axis, and the near-total dominance of the subcutaneous route. Units cause more reported errors than any of it — 1 mg is 1,000 mcg, and IU is a different kind of unit entirely.
- Half-life sets the clock. Native peptides that clear in minutes get frequent or pulsed dosing in study designs; engineered long-acting analogs get weekly schedules. The frequency is chemistry, not preference.
- Titration ladders exist to manage tolerability. GLP-class trials escalate stepwise over weeks because gastrointestinal effects are dose-dependent and fade with time at each step.
- Cycling reflects receptor adaptation. Continuous stimulation can desensitize signaling — a core reason some study designs use on-off structures and pulsed timing.
- Most reported dosing errors are unit errors — nearly always a factor-of-1,000 slip between mg and mcg.
- The primary sources are public. ClinicalTrials.gov publishes registered protocol structures for anyone to read.
Why dosing is structured at all
Strip away the compound names and nearly every published peptide protocol is answering the same three questions.
How fast does the molecule clear? Peptides span an enormous half-life range. Many native peptides are degraded within minutes of entering circulation, which is why study designs for them use frequent or specifically timed administration. At the other extreme, modern GLP-class analogs are deliberately engineered — through fatty-acid chains that bind albumin and substitutions that resist enzymatic breakdown — to persist for days, which is what makes once-weekly trial dosing possible. When you see a protocol's frequency, you are reading the molecule's clearance in disguise.
What happens to the receptor under constant signal? Receptors exposed to continuous stimulation can downregulate or desensitize — the signal fades even as the input stays constant. This is a central reason some study designs pulse doses, space them, or build in off periods rather than maintaining a constant level.
What effects need managing over time? In the GLP class, gastrointestinal effects — nausea foremost — are dose-dependent and most pronounced when a dose level is new. That single fact explains the most recognizable structure in the modern literature, covered next.
Four patterns that repeat across the literature
| pattern | what it looks like in a protocol | the reason behind it |
|---|---|---|
| Titration ladder | Start low, step the dose up at intervals of weeks until reaching a target or maximum-tolerated level. | Dose-dependent GI effects in the GLP class fade with time at each step; the ladder buys that time. |
| Cycling | Defined on-periods and off-periods, or pulsed rather than continuous administration. | Receptor desensitization under constant stimulation; some designs also cycle to isolate effects. |
| Meal-relative timing | GH-axis study designs administer in fasted states — away from meals. | Elevated glucose and insulin blunt growth hormone release in study models; fasted timing preserves the measured response. |
| Subcutaneous route | Injection into subcutaneous tissue dominates protocols across classes. | Digestion destroys peptide chains, so oral bioavailability is generally poor; subcutaneous delivery gives the intact molecule predictable absorption. |
None of these patterns is a rule of nature — they are design responses to the three questions above, and you will find published exceptions to each. But once you can name them, an unfamiliar protocol stops looking like arbitrary numbers and starts reading as a set of decisions with visible reasons.
Units literacy — where the real errors live
Here is the least glamorous and most important section on this page. The dosing errors commonly reported in the literature and in research communities are overwhelmingly not pharmacology errors. They are arithmetic errors, and nearly always the same one: confusing milligrams with micrograms — a factor of 1,000.
| unit | measures | conversion | note |
|---|---|---|---|
| mg — milligram | mass | 1 mg = 1,000 mcg | The unit vials are labeled in. A 5 mg vial holds 5,000 mcg. |
| mcg / µg — microgram | mass | 1,000 mcg = 1 mg | The unit many published protocol amounts are stated in. µg and mcg are the same unit. |
| mL — milliliter | volume | 1 mL = 1,000 µL | Volume of liquid — meaningless for dosing until you know the concentration in it. |
| IU — international unit | biological activity | defined per substance | Not a mass unit. Common in older GH literature. No universal IU-to-mg conversion exists across compounds. |
Two habits keep the literature readable. First, convert everything to one unit before comparing anything — a protocol stated in mcg and a vial labeled in mg are describing the same kind of quantity three decimal places apart. Second, treat IU as its own category: it measures activity, not mass, so an IU figure from one compound's literature tells you nothing about another compound's. When mass and volume meet — how many mcg sit in each mL of a reconstituted vial — that is concentration math, which has its own fundamentals page.
How to read a clinical protocol yourself
You do not need us, or anyone, to summarize the research for you. Registered trial designs are public at ClinicalTrials.gov, and reading one takes minutes once you know where to look.
- Search the compound name — generic name, not brand — and filter to interventional studies.
- Open the study design section. Note the phase, arm count, and whether it is placebo-controlled. Early-phase dose-finding studies are where escalation structures are most explicit.
- Read the arms and interventions. This is where the actual structure lives: dose levels, route, frequency, and any escalation schedule, stated plainly.
- Check duration and endpoints. How long the protocol ran and what it measured tell you what the dosing structure was built to detect.
- Read three or four trials, not one. The structural patterns — ladders, spacing, route — become obvious across a handful of protocols in a way no single study shows.
Published results papers add a further layer — tolerability data by dose level, discontinuation rates, response curves — but the registry alone answers the structural question this page is about: how researchers organized dosing, and why.
What this page is not
Everything above describes how published research protocols were structured and why those structures exist. None of it is a recommendation, a starting point, or a template — and the gap between a trial protocol and any individual situation is not a detail. Trial dosing happens under screening, exclusion criteria, monitoring, and medical supervision, and even inside that controlled setting, individual response varies widely — the tolerability tables in any GLP-class paper show the same dose producing very different experiences across participants. What the literature reports about adverse effects, and how to read that evidence, has its own fundamentals page. Read the protocols as what they are: documentation of research design, not guidance.
FAQ
Why do different sources report such different protocol amounts for the same peptide?
Usually three reasons: different study phases ask different questions [dose-finding studies span wide ranges by design], different routes and frequencies change the relevant amounts, and unit sloppiness — one source in mg, another in mcg — makes identical protocols look a thousandfold apart. Go to the registered protocol and read the arms directly.
What does "maximum tolerated dose" mean in a protocol?
It is a formal endpoint in early-phase research — the highest dose level at which adverse effects stayed within the study's predefined acceptability threshold. It is a property of that study's design and population, not a general property of the compound.
Why do older GH papers use IU while newer ones use mg?
Growth hormone was historically quantified by biological activity — international units — before purified standards made mass dosing the norm. Conversion factors exist for GH specifically because its standards were formalized, but the general lesson holds: IU is substance-specific, and cross-compound IU comparisons are meaningless.
Is community-reported dosing a reliable source?
It is descriptive data about what people report, with all the selection and reporting biases that implies — no controls, no verification of compounds or amounts, and survivorship effects in what gets posted. We treat it as market information, not evidence. The registered literature is the primary source.
References & further reading
- ClinicalTrials.gov, registry of clinical research studies — clinicaltrials.gov
- FDA, Drugs — regulatory framework and drug development resources — fda.gov
this page is descriptive documentation of published research design — it is not dosing guidance, a recommendation, or a protocol for use. research + education only · not medical advice. see our editorial policy.